SUMMARY
Effective therapy of atherosclerotic complications in patients with chronic kidney disease (CKD) is an unmet clinical need. Cardiovascular events are the most common cause of death. At a glomerular filtration rate #60 ml/min, these events are increased also after correction for common risk factors. Previous studies have Traditional risk factors such as cholesterol profile are poor prognostic markers in this population (5, 6) .
Thus, it is likely that additional mediators modulate atherosclerosis development in CKD.
Inflammatory leukocytes are central in plaque development (7) (8) (9) . The most prominent vascular leukocytes in atherosclerosis are myeloid mononuclear phagocytes, mostly termed macrophages.
Both lipid scavenging and antigen presentation have been demonstrated for this cell type. In moderate renal impairment, arterial wall inflammation increases in mouse models of atherosclerosis, with a prominent increase in macrophages, their CD11c expression and antigen-presenting function (10, 11 ). An autopsy study found more leukocytes in the arterial wall in patients with nondialysis-dependent CKD than in patients with normal kidney function (12) . Two recent studies found increased aortic wall glucose metabolism in human CKD stage III, indicating enhanced vascular wall inflammation also in patients without clinical atherosclerotic endpoints (13, 14) .
Impaired kidney function profoundly alters immune regulation (15, 16) . Blood levels of interleukin (IL)-17A-producing T cells were elevated in small cohorts of patients with advanced CKD (17, 18) . In animal models with defined, more moderate reduction of renal function, we, along with others, have found upregulation of the T-cell cytokine IL-17A in inflammation (11, 19) . IL-17A and its main receptor subunit, IL-17 receptor A, regulate myeloid response in infection and sterile inflammation (20) . IL-17A can directly modulate myeloid cell functions (21-23) but also act on resident vascular cells (24) (25) (26) . The role of IL-17A in experimental atherosclerosis is diverse. Decisive factors may include the level of IL-17A expression and its balance with other cytokines (8, 27, 28) resulting in proatherogenic function in nascent plaques in renal impairment (10, 11) .
In addition to plaque formation, the level of inflammation critically influences further plaque development, determining lesion stability and the risk of plaque rupture (7) (8) (9) . Animal models have shown distinct macrophage provenance in nascent lesions and established atheroma. Recruitment of monocytic cells from the circulation is largely replaced by local proliferation in mature plaques (29, 30) . Thus, possible anti-inflammatory interventions will need to be tailored to established lesions. After washing twice with phosphate-buffered saline, the aortas were digested as described elsewhere (11 Nordlohne et al.
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ENZYMATIC DIGESTION OF TISSUES AND FLOW
CYTOMETRY. Preparation and enzymatic digestion of tissues were as described elsewhere (11) . For assessment of IL-17A production, cells were stimulated for 5 h with 10 ng/ml of phorbol 12-myristate 13-acetate and 500 ng/ml of ionomycin (both Sigma-Aldrich, St.
Louis, Missouri). The following antibodies were used: to 40% in LDLr -/-mice, was performed (10,11).
Atherosclerosis was induced by a high-fat diet for 20 weeks ( Figure 1A ). There were no significant differences in body weight, blood counts, and plasma lipids between control-operated and unilaterally nephrectomized mice of each genotype (Supplemental Staining for a-smooth muscle actin in the lesions was very similar (Supplemental Figure 2 ).
These data demonstrate a profound effect of IL-17 receptor A on atherosclerotic lesion size in renal impairment.
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ENDOTHELIAL CELL IL-17 RECEPTOR A PROMOTES PRO-INFLAMMATORY CHEMOKINE EXPRESSION.
The endothelium has been implicated in vascular IL-17A effects (25, 36, 37) . It expressed IL-17 receptor A, the main receptor subunit ( Figure 5A ). IL-17 receptor C, the subunit required for IL-17A and IL-17F signaling and IL-17 receptor E mRNA, required for IL-17C signaling, were also detected. IL-17 receptor B
(required by IL-17E ¼ IL-25) was below detection limit.
The effect of recombinant IL-17A and IL-17F on endothelial cell cytokine and chemokine expression was studied. Indeed, CXCL1, CCL2, IL-6, and granulocytemacrophage colony-stimulating factor (GM-CSF) mRNA were significantly upregulated by IL-17A
( Figures 5B to 5E ). An equal dose of IL-17F induced a significant, but weaker, CXCL1 response (Figures 5F to 5I). These data suggest the endothelium as an additional IL-17A signal responder in atherosclerotic inflammation.
Indeed, CXCL1, CCL2, and IL-6 mRNA levels also tended to be higher in the atherosclerotic aortas of LDLr -/-mice with renal impairment than in identically treated Il17ra -/-LDLr -/-animals (Supplemental Figure 7) . In addition, IL-17F, which was above mRNA detection limits in atherosclerotic aortas, was lower in Il17ra -/-LDLr -/-mice than in LDLr -/-mice.
Decrease of these cytokines that can promote aortic myeloid cell accumulation in atherosclerosis Nordlohne et al.
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 3 , N O . 1 , 2 0 1 8
Atherosclerotic Inflammation in Uremia Figures 8C and 8D ).
IL-17A BLOCKADE NORMALIZES ENHANCED LESION SIZE AND AORTIC INFLAMMATION DESPITE RENAL
IMPAIRMENT. As an independent method and possible therapeutic approach of IL-17A antagonism,
anti-IL-17A antibody treatment compared with isotype control was used. It was started at the same time point, after 6 weeks of a high-fat diet, and continued for 6 weeks in LDLr -/-mice with normal and impaired renal function ( Figure 6A ). Supplemental Table 4 illustrates that there was no significant difference between the 4 experimental groups in the following: body, heart, or spleen weight; plasma electrolytes; lipids; blood counts; or blood pressure. Remnant kidney weight increased similarly in anti-IL-17A and control IgG-treated groups. Renal function was determined by fluorescein isothiocyanate-sinistrin clearance; it was significantly decreased in the unilateral nephrectomy groups, irrespective of antibody type (Supplemental Figure 9) . Peripheral blood and spleen leukocyte composition was not significantly altered (Supplemental Figure 10) . With IL-17A
blockade, the proportion of splenic IL-17A producers and splenic RORgt mRNA tended to increase (Supplemental Figure 11) , whereas GM-CSF as a possible downstream effector was decreased (Supplemental Figure 12 ).
Atherosclerotic root lesions were far advanced at the end of the experiment ( Figure 6B ). They were significantly larger in mice with renal impairment receiving control isotype IgG compared with all other groups; that is, compared with mice with and 50% Il17ra -/-(CD45.2) bone marrow were kept on a high-fat diet for 6 weeks, and aortic CD11b þ CD11c þ myeloid phagocytes analyzed by using flow cytometry.
Data are expressed as proportion of Il17ra -/-(CD45.2) cells in mice after RI compared with identically treated control operated (ctrl) mice from the same bone marrow transplantation (n ¼ 8 per group from 3 independent transplantations). Abbreviations as in Figures 1 and 3 .
normal renal function and mice with renal impairment treated with IL-17A-blocking antibody ( Figure 6C) . Differential histological plaque analysis revealed similar relative distribution of cellular and lipid-rich and fibrotic areas determined by using
Masson's trichrome and Picrosirius red stain (Supplemental Figure 13) . Staining for a-smooth muscle actin revealed similar contents in the caps of Nordlohne et al.
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